A federal trial court in Massachusetts March 26 refused to dismiss a whistleblower’s suit alleging that Texas-based pharmaceutical manufacturer Healthpoint Ltd. violated the False Claims Act by submitting reimbursement claims for a topical wound ointment, Xenederm, that was ineligible for payment because an identical drug’s effectiveness determination had been rescinded (United States ex rel. Conrad v. Healthpoint Ltd.).
Relator Constance A. Conrad initially sued a number of pharmaceutical manufacturers and distributors under the qui tam provisions of the FCA in 2002. After investigating her complaint, the United States filed a separate three-count complaint against Healthpoint Ltd. in 2011. ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.